Literature DB >> 17998161

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.

Lorna Piazzi1, Andrea Cavalli, Francesco Colizzi, Federica Belluti, Manuela Bartolini, Francesca Mancini, Maurizio Recanatini, Vincenza Andrisano, Angela Rampa.   

Abstract

The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998161     DOI: 10.1016/j.bmcl.2007.09.100

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  37 in total

1.  A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.

Authors:  Ziyad F Al-Rashid; Richard P Hsung
Journal:  Bioorg Med Chem Lett       Date:  2015-06-27       Impact factor: 2.823

2.  Sphingosylphosphorylcholine attenuated β-amyloid production by reducing BACE1 expression and catalysis in PC12 cells.

Authors:  Hyoseok Yi; Seong Jin Lee; Jiyeong Lee; Chang-Seon Myung; Woo-Kyu Park; Hee-Jong Lim; Ge Hyeong Lee; Jae Yang Kong; Heeyeong Cho
Journal:  Neurochem Res       Date:  2011-06-15       Impact factor: 3.996

Review 3.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

4.  (+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.

Authors:  Ziyad F Al-Rashid; Richard P Hsung
Journal:  Bioorg Med Chem Lett       Date:  2010-12-16       Impact factor: 2.823

5.  sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.

Authors:  Anthony J Veloso; Devjani Dhar; Ari M Chow; Biao Zhang; Derek W F Tang; Hashwin V S Ganesh; Svetlana Mikhaylichenko; Ian R Brown; Kagan Kerman
Journal:  ACS Chem Neurosci       Date:  2012-11-20       Impact factor: 4.418

6.  Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity.

Authors:  Daniel Silva; Mourad Chioua; Abdelouahid Samadi; Paula Agostinho; Pedro Garção; Rocío Lajarín-Cuesta; Cristobal de Los Ríos; Isabel Iriepa; Ignacio Moraleda; Laura Gonzalez-Lafuente; Eduarda Mendes; Concepción Pérez; María Isabel Rodríguez-Franco; José Marco-Contelles; M Carmo Carreiras
Journal:  ACS Chem Neurosci       Date:  2013-02-04       Impact factor: 4.418

7.  Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease.

Authors:  Cai Zhiyou; Yan Yong; Sun Shanquan; Zhang Jun; Huang Liangguo; Yan Ling; Li Jieying
Journal:  Neurochem Res       Date:  2009-01-04       Impact factor: 3.996

8.  Characterization of the interactions between coumarin-derivatives and acetylcholinesterase: Examination by NMR and docking simulations.

Authors:  Nazish U Tanoli; Sheraz A K Tanoli; Antonio G Ferreira; Mazhar Mehmood; Sana Gul; Julia L Monteiro; Lucas C C Vieira; Tiago Venâncio; Arlene G Correa; Zaheer Ul-Haq
Journal:  J Mol Model       Date:  2018-07-14       Impact factor: 1.810

Review 9.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 10.  BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

Authors:  Arun K Ghosh; Heather L Osswald
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.